New posts today from Dr. Max Lataillade about Lero
Post# of 153880
(Total Views: 1456)
Posted On: 02/17/2025 1:13:03 PM
New posts today from Dr. Max Lataillade about Leronlimab on LinkedIn (and the posts were “liked” by multiple CYDY employees). Here are his posts:
“While I am not an oncology expert, my background is in infectious diseases and HIV, with a deep understanding of immunology and extensive experience in drug development. When evaluating new approaches to treatment and cure, I focus on the mechanism of action (MOA), how well it addresses the underlying process, and, most importantly, how inhibiting that process meets unmet medical needs. This perspective is what makes CCR5 inhibition-particularly with agents like Leronlimab so intriguing in metastatic colorectal cancer and triple negative breast cancer.”
And:
“Unpacking CCR5 Inhibition: A Promising Therapeutic Target with Broad Applications
CCR5 (C-C chemokine receptor type 5) is a cell surface receptor that plays a pivotal role in immune cell signaling, particularly in inflammatory responses and the recruitment of immune cells to sites of infection. Most notably, it serves as a coreceptor for HIV, facilitating the virus's entry into cells and subsequent infection. Beyond its role in HIV, CCR5 has been implicated in a variety of diseases, including cancer, cardiovascular disease, fibrosis, and autoimmune conditions, due to its involvement in immune cell trafficking and inflammatory pathways. Recently, attention has shifted toward its role in oncology. CCR5 contributes to the spread of cancer through multiple processes: it promotes angiogenesis to support tumor growth, skews macrophages toward a pro-tumor M2 phenotype, aids in the spread of distant metastases, neutralizes chemotherapy effects by promoting DNA repair, and recruits immunosuppressive CCR5+ regulatory T cells into the tumor microenvironment. Therefore, therapeutic strategies targeting CCR5 to block its activity could hold significant promise as part of future treatment pathways.”
I remain… #BULLISH
“While I am not an oncology expert, my background is in infectious diseases and HIV, with a deep understanding of immunology and extensive experience in drug development. When evaluating new approaches to treatment and cure, I focus on the mechanism of action (MOA), how well it addresses the underlying process, and, most importantly, how inhibiting that process meets unmet medical needs. This perspective is what makes CCR5 inhibition-particularly with agents like Leronlimab so intriguing in metastatic colorectal cancer and triple negative breast cancer.”
And:
“Unpacking CCR5 Inhibition: A Promising Therapeutic Target with Broad Applications
CCR5 (C-C chemokine receptor type 5) is a cell surface receptor that plays a pivotal role in immune cell signaling, particularly in inflammatory responses and the recruitment of immune cells to sites of infection. Most notably, it serves as a coreceptor for HIV, facilitating the virus's entry into cells and subsequent infection. Beyond its role in HIV, CCR5 has been implicated in a variety of diseases, including cancer, cardiovascular disease, fibrosis, and autoimmune conditions, due to its involvement in immune cell trafficking and inflammatory pathways. Recently, attention has shifted toward its role in oncology. CCR5 contributes to the spread of cancer through multiple processes: it promotes angiogenesis to support tumor growth, skews macrophages toward a pro-tumor M2 phenotype, aids in the spread of distant metastases, neutralizes chemotherapy effects by promoting DNA repair, and recruits immunosuppressive CCR5+ regulatory T cells into the tumor microenvironment. Therefore, therapeutic strategies targeting CCR5 to block its activity could hold significant promise as part of future treatment pathways.”
I remain… #BULLISH
(40)
(0)